TriSalus Life Sciences (TLSI) Expected to Announce Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $9.04 million for the quarter.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The company had revenue of $9.17 million during the quarter, compared to analysts' expectations of $9.04 million. During the same period last year, the company earned ($0.60) earnings per share. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Stock Up 0.8%

TLSI stock traded up $0.04 during midday trading on Monday, reaching $5.18. 48,808 shares of the company's stock traded hands, compared to its average volume of 43,006. The company has a 50-day simple moving average of $5.40 and a two-hundred day simple moving average of $5.02. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.17. The company has a market cap of $167.17 million, a price-to-earnings ratio of -2.08 and a beta of 0.50.

Institutional Investors Weigh In On TriSalus Life Sciences

An institutional investor recently bought a new position in TriSalus Life Sciences stock. Goldman Sachs Group Inc. acquired a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 33,900 shares of the company's stock, valued at approximately $187,000. Goldman Sachs Group Inc. owned 0.11% of TriSalus Life Sciences as of its most recent SEC filing. 2.58% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TLSI shares. Lake Street Capital started coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They set a "buy" rating and a $10.00 price target for the company. Roth Mkm reaffirmed a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $10.93.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.